Klow

• **GHK-Cu** — a copper tripeptide, studied in the context of collagen production.
• **BPC-157** — a pentadecapeptide, studied in models of tissue healing.
• **TB-500** — a fragment of thymosin beta-4, associated with cell migration.
• **KPV** — a tripeptide, a fragment of alpha-MSH, studied in models of inflammation.

KLOW is the established abbreviation for a mixture of four substances, all of

which are also available separately in our catalog:

The strength stated is the **combined mass of all four substances**. The ratio of

the individual components is given in the certificate of analysis for the batch

and differs between manufacturers.

The combination has no mechanism of its own — the action of each component is

described in its own entry. The mixture is built on the assumption that the

substances act at different levels of healing: vessel formation, cell migration,

matrix synthesis and the inflammatory response.

• Tissue healing and remodelling.
• The inflammatory response in skin.
• Comparative studies of mixtures against the individual substances.

There is literature for every component, predominantly preclinical. **For the

combination as a whole there are no controlled studies.** The claim of synergy is

a hypothesis derived from the mechanisms of the individual substances, not a finding.

With mixtures there is the further point that any observed effect cannot be

attributed to a particular component — a fundamental limitation for research use.

If the experiment needs to establish which substance is responsible for what,

the separate items are the better choice.

Both TB-500 and thymosin beta-4 appear on the Prohibited List of the World

Anti-Doping Agency (WADA). This item is a **reference standard intended strictly

for laboratory and research use**. It is neither a medicine nor a cosmetic and we

provide no dosing or health advice with it.